Compare TG Therapeutics Inc (TGTX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Clear Secure Inc — how do they compare? TG Therapeutics Inc trades at $55.14 (market cap $8.16B), while Clear Secure Inc trades at $42.77 (market cap $4.44B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Clear Secure Inc pays a 1.33% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Clear Secure Inc for 19 Days on average.
| TGTX | YOU | |
|---|---|---|
Market Cap | $8.16B | $4.44B |
Volume | 1,735,121 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $59.06 | $62.36 |
52-Week Low | $26.94 | $29.61 |
Typical Hold Time | 16 Days | 19 Days |
Enterprise Value | $8.37B | $3.59B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Clear Secure (YOU) trades at $43.55, up 2.28% today, with a bullish technical signal despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with $0.49 EPS, and shows robust revenue growth and profitability, including a 66.66% gross margin. Recent news highlights strategic partnerships, such as with CrowdStrike, and positive analyst coverage.
The outlook is positive, driven by accelerating membership growth and expanding margins, but risks include high valuation multiples and potential market volatility. Analysts have a consensus price target of $61.40, suggesting upside, with 44% buy ratings indicating cautious optimism amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
